Values First Advisors Inc. Decreases Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

Values First Advisors Inc. decreased its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 5.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,977 shares of the technology company’s stock after selling 2,111 shares during the period. Values First Advisors Inc. owned approximately 0.19% of Simulations Plus worth $1,059,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. First Horizon Advisors Inc. grew its holdings in shares of Simulations Plus by 82.6% in the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock worth $26,000 after purchasing an additional 370 shares during the last quarter. nVerses Capital LLC grew its holdings in Simulations Plus by 1,100.0% in the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after acquiring an additional 1,100 shares during the last quarter. Quantbot Technologies LP bought a new stake in Simulations Plus in the 3rd quarter worth $59,000. US Bancorp DE increased its position in shares of Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock valued at $159,000 after acquiring an additional 1,343 shares during the period. Finally, Pitcairn Co. raised its stake in shares of Simulations Plus by 9.1% during the third quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock valued at $211,000 after acquiring an additional 549 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Insider Activity at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 19.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp lifted their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. BTIG Research decreased their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, October 24th. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, Stephens assumed coverage on shares of Simulations Plus in a research report on Friday, November 15th. They set an “overweight” rating and a $39.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.40.

Simulations Plus Trading Down 2.1 %

Shares of SLP stock opened at $36.05 on Wednesday. The company’s fifty day moving average price is $30.91 and its 200-day moving average price is $32.32. Simulations Plus, Inc. has a 12 month low of $24.00 and a 12 month high of $51.22. The stock has a market cap of $724.24 million, a PE ratio of 90.13 and a beta of 0.83.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.